NovaBridge Biosciences (NBP)’in fiyatı nedir?

NovaBridge Biosciences (NBP)’in fiyatı $1.79’dir

NovaBridge Biosciences (NBP)’in piyasa değeri nedir?

NovaBridge Biosciences (NBP)’in piyasa değeri $205.75M’dir.

NovaBridge Biosciences (NBP) Geliri

NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.

Yıl	Gelir	Değiştir
Sağlanan tarihler için yeterli veri yok.

Yıl

Gelir

Değiştir

Sağlanan tarihler için yeterli veri yok.

Şirket	Gelir	Gelir Farkı	Ülke
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Moderna, Inc. MRNA.US	$2.23B	-	US
CSL Limited CSL.AX	$15.74B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Şirket

Gelir

Gelir Farkı

Ülke